Life sciences span a wide range of disciplines that study living organisms in six categories, from molecules and cells to ecosystems and human health. The category that intersects in our world is Applied Life Sciences. And more specifically these fields that translate biological knowledge into practical solutions.
- Biotechnology – using living systems for technology and innovation
- Pharmacology – drug action and development
- Biomedical Science – disease mechanisms, diagnostics, therapeutics
- Stem Cell Biology & Regenerative Medicine – cell-based therapies
In this monthly report you will find news and highlights in the Applied Life Sciences.
Biotechnology
Biotium Introduces Flexible, Time-Saving, and Cost-Effective Fluorescent Labeling for HaloTag® Fusion Proteins
Biotium, a provider of innovative fluorescent reagents and kits for life science research, announces the release of a new line of bright fluorescent ligands designed for flexible labeling of HaloTag® self-labeling protein tags in live or fixed cells. ViaTag™ Haloalkane Ligands are available in 11 fluorescent colors spanning blue to near-infrared, to support a wide range of multicolor imaging and flow cytometry applications. ViaTag™ Haloalkane ligands provide rapid covalent labeling with minimal background and no extensive wash steps for streamlined labeling protocols and lower overall cost.
Freudenberg Medical Ushers in a New Era for Hydrophilic Coatings with Launch of LUBRITEQ™
Freudenberg Medical, a global contract design and manufacturing (CDMO) partner to the medical device and biopharma industry, announced the launch of LUBRITEQ™, a new high-performance hydrophilic coating solution, along with a comprehensive suite of associated development and manufacturing services. LUBRITEQ™ is now available globally across Freudenberg Medical’s vertically integrated operations.
Pharmacology
Pharmaceutical Service Provider Vetter Pharma to Build New Manufacturing Site in Germany
Vetter, a pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant milestone in the company’s long-term global growth strategy. Construction is scheduled to begin in the second quarter of 2026. Initially, approximately €480 million have been allocated for the first construction phase of the new commercial production plant. Operations are expected to commence in 2031.
MetP Pharma’s Neural Targeting Drug Delivery Technology Sets a New Benchmark for Brain Delivery of Peptides
MetP Pharma AG, a pioneer in nose-to-brain drug delivery, highlights the differentiated advantages of its proprietary nose-to-brain drug delivery technology (DDT) compared with systemic blood–brain barrier (BBB) transporter approaches such as BrainShuttle™ or other targeting approaches.
Biomedical
BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease
BioMed X, an innovation hub for pharma, announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme.
Hemex Health Receives FDA Breakthrough Device Designation for Gazelle® Hb Variant Test
Hemex Health, a medical diagnostics company focused on decentralized testing for blood-based conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its Gazelle® Hb Variant Test.
Stem Cell Biology & Regenerative Medicine
Michigan Integrative Health Expands Stem Cell Therapy Services to Welcome Canadian Patients
Michigan Integrative Health Stem Cells, a provider of stem cell therapy and regenerative medicine in Shelby Township, Michigan, announces the expansion of its service area to welcome patients from Southwestern Ontario, Canada. The clinic now actively serves individuals traveling from Windsor, Sarnia, Chatham, London, and Kitchener and more, who are seeking drug-free, non-surgical solutions for chronic pain and complex health conditions.
Clinical Studies and Trials
ConcertAI Launches Accelerated Clinical Trials, Leveraging Agentic AI to Radically Shorten Trial Timelines
ConcertAI, an oncology real-world evidence and AI SaaS technology company, unveiled Accelerated Clinical Trials (ACT), an enterprise agentic artificial intelligence (AI) platform designed to automate and inject predictive intelligence across the end-to-end clinical trial process. Launched at Summit for Clinical Ops Executives (SCOPE) 2026 in Orlando, ACT integrates real-world and proprietary data with advanced AI workflows to help sponsors and contract research organizations (CROs) shorten overall trial timelines by 10 to 20 months, significantly reduce costs, and bring therapies to market faster.
New Therapy Could Make Life Better for Kidney Transplant Patients
A new study offers hope that kidney transplant patients could one day have a monthly treatment instead of multiple pills every day. The new treatment also may reduce side effects and increase the lifespan of the donor organ.
Dr. Eric Leuthardt to Present Randomized Controlled Trial results on IpsiHand® at International Stroke Conference 2026
Kandu, Inc., a healthcare technology company developing brain-computer interface–enabled solutions for post-stroke recovery, announced that Dr. Eric Leuthardt will present results of a randomized controlled trial studying the IpsiHand® system at the International Stroke Conference (ISC) 2026, taking place February 4–6, 2026, in New Orleans, Louisiana.
PhaseV Launches AI-Powered Enrollment Lab: Eliminating Guesswork & Grounding Study Design in Clinical Reality
PhaseV recently announced the launch of its new Enrollment Lab solution at the 17th Annual SCOPE Summit. A high-impact addition to the PhaseV ClinOps platform, this AI-powered solution enables sponsors to quantify a study’s true enrollment potential and model the impact of protocol trade-offs prior to protocol lock.
ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury
ONWARD Medical, the neurotechnology company pioneering spinal cord stimulation therapies to restore movement, function, and independence, announces the enrollment of the first participant in Empower BP, a global pivotal study assessing the safety and effectiveness of the investigational ARC-IM® System in managing symptomatic blood pressure instability in people with chronic spinal cord injury (SCI).